Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03909152 · ClinicalTrials.gov registry record · Phase 2
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03909152: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03909152 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03909152, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.
Interventions
- DRUG Onapristone ER
- DRUG Onapristone ER + Anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2024-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03909152
The ClinicalTrials.gov registry entry for NCT03909152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Onapristone ER is the first listed.
NCT03909152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03909152 about?
NCT03909152 is a clinical study titled "A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone". The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.
What is the current status of trial NCT03909152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-05-02. Estimated completion is 2024-09-03.
What interventions are being tested in trial NCT03909152?
The interventions under investigation include: Onapristone ER (DRUG), Onapristone ER + Anastrozole (DRUG).
Who is sponsoring clinical trial NCT03909152?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.